Bactiguard Holding AB

Bactiguard operates with a debt-to-equity ratio of 0.52 and a current ratio of 1.67, indicating moderate leverage and acceptable short-term liquidity. The company holds 44.26 million SEK in cash and equivalents but has 162.92 million SEK in long-term debt, resulting in negative net cash. Free cash flow of 33.51 million SEK contrasts with negative operating cash flow of 1.49 million SEK, suggesting capital expenditures are driving cash generation. Profitability metrics show a return on equity of -2.49% and return on assets of -1.44%, both below industry norms for medical equipment firms. Operating income of -3.32 million SEK and net loss of -7.84 million SEK indicate ongoing operational challenges despite 215.92 million SEK in revenue. Gross profit of 133.06 million SEK represents 61.6% of revenue, suggesting strong product margins but insufficient to offset SG&A and R&D expenses. Geographically, the company is concentrated in Sweden with secondary distribution in Portugal and Zambia. No segment-specific revenue breakdown is available, but the product portfolio includes Foley catheters, endotracheal tubes, and central venous catheters. The lack of geographic diversification and segment granularity increases exposure to regional healthcare policy shifts. Revenue growth has been flat, with actual revenue of 228.8 million SEK slightly exceeding the 216 million SEK analyst estimate. Earnings per share remain negative, with a -0.22 SEK actual EPS versus -0.64 SEK estimated. Analysts have uniformly set a 15.00 SEK price target, suggesting limited upside potential. Risk factors include liquidity constraints from negative net cash and ongoing operating losses. Dilution risk is assessed as low, with no near-term pressure from share issuance. However, the company's reliance on R&D for product differentiation and the capital-intensive nature of medical device manufacturing pose long-term risks. Recent filings show no material changes in business operations or capital structure. The company continues to focus on expanding its product line and geographic reach through distribution agreements, but no new product launches or regulatory approvals were disclosed in the latest reports.